ROIV Earnings Date: Nov 9, 2026 (Estimated) — Roivant Sciences Ltd.
NASDAQ · Healthcare · Biotechnology
Updated
When is ROIV's next earnings date?
Roivant Sciences Ltd. (ROIV) is expected to report Q2 2027 earnings on Monday, November 9, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.37 on revenue of $4.1M.
How did ROIV do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q1 2027), Roivant Sciences Ltd. posted EPS of -$0.34 versus the -$0.30 estimate, a miss of 8.1%. Revenue was $1.4M against a $2.1M estimate. The stock's 1-day post-earnings move was +1.5%.
How much does ROIV stock move after earnings?
ROIV beat EPS estimates in 7 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 6.1% (up or down) in the day after earnings.
About Roivant Sciences Ltd.
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q1 2027 | -0.30 | -0.34 | +8.11% | $1.4M | ❌ Miss | +1.50% | +4.51% | -0.55% |
| 2026-05-20 | Q4 2026 | -0.36 | -0.27 | +23.89% | $2.5M | ✅ Beat | +14.89% | +4.86% | +11.41% |
| 2026-02-06 | Q3 2026 | -0.34 | -0.24 | +29.41% | $2.0M | ✅ Beat | +22.14% | +26.54% | +39.69% |
| 2025-11-10 | Q2 2026 | -0.32 | -0.28 | +12.50% | $1.6M | ✅ Beat | +2.67% | -1.60% | -0.92% |
| 2025-08-11 | Q1 2026 | -0.26 | -0.25 | +3.85% | $2.2M | ✅ Beat | -2.79% | +3.13% | +17.32% |
| 2025-02-10 | Q3 2025 | -0.24 | -0.20 | +16.67% | $9.0M | ✅ Beat | -0.92% | -3.03% | -3.12% |
| 2024-05-30 | Q4 2024 | -0.30 | -0.19 | +36.67% | $28.9M | ✅ Beat | -3.17% | +1.40% | -1.49% |
| 2024-02-13 | Q3 2024 | -0.32 | -0.21 | +34.38% | $37.1M | ✅ Beat | -0.64% | +6.16% | -2.30% |
Showing last 8 quarters.